Chondrodysplasia, Grebe type
Chondrodysplasia, Grebe type is a rare genetic disorder characterized by severe skeletal abnormalities. It is a form of chondrodysplasia, which refers to a group of disorders that affect the development of cartilage and bone. This condition is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected.
Clinical Features
Individuals with Chondrodysplasia, Grebe type typically present with:
- Short stature
- Severe shortening of the limbs (micromelia)
- Malformations of the hands and feet, including brachydactyly (short fingers and toes) and syndactyly (webbed fingers and toes)
- Joint abnormalities, such as contractures and limited range of motion
- Facial abnormalities, including a prominent forehead and a depressed nasal bridge
Genetics
Chondrodysplasia, Grebe type is caused by mutations in the GDF5 gene, which encodes a protein that is crucial for the development of bones and joints. The GDF5 protein is a member of the bone morphogenetic protein (BMP) family, which plays a key role in the formation of cartilage and bone during embryonic development.
Diagnosis
The diagnosis of Chondrodysplasia, Grebe type is based on clinical evaluation, family history, and genetic testing. Radiographic imaging can reveal characteristic skeletal abnormalities, and molecular genetic testing can confirm the presence of mutations in the GDF5 gene.
Management
There is no cure for Chondrodysplasia, Grebe type, and treatment is primarily supportive. Management may include:
- Physical therapy to improve mobility and prevent joint contractures
- Orthopedic interventions, such as surgery, to correct skeletal deformities
- Occupational therapy to assist with daily activities
Epidemiology
Chondrodysplasia, Grebe type is an extremely rare condition, with only a few cases reported in the medical literature. It affects both males and females equally and has been identified in various populations around the world.
See Also
References
External Links
-
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
